Japan's Parliament Backs Dovish BOJ Board Members, Raising Questions on Rate Hike Path 
Asian Currencies Hold Steady Amid Iran Conflict and Central Bank Decisions 
Asian Markets Mixed as Oil Volatility and Inflation Fears Weigh on Sentiment 
Bank of Japan Holds Rates Steady Amid Inflation Concerns and Yen Weakness 
Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict 
Asian Currencies Slide as Oil Prices Surge Amid U.S.-Israel-Iran Conflict 
Gold Prices Stabilize in Asian Trade Amid Rate Uncertainty and Iran War Concerns 
BOJ Holds Interest Rates Steady Amid Middle East Uncertainty 
China Holds Lending Rates Steady Amid Global Oil Price Surge and Middle East Tensions 
NVIDIA Resumes China AI Chip Production Amid $1 Trillion Revenue Forecast 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
Iran-Israel War Escalates: Energy Infrastructure Attacks Shake Global Oil Markets 
BHP Appoints Brandon Craig as New CEO, Succeeding Mike Henry 
Global Central Banks Hold Rates Amid Iran War-Driven Energy Price Surge 
HSBC Considers Cutting 20,000 Jobs Amid AI-Driven Transformation 
Asian Markets Tumble as BOJ Holds Rates, Oil Surges Past $110 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
